In bladder and prostate cancers, treatment with chemotherapeutic agents such as gemcitabine or paclitaxel induces the release of HMGB1, which subsequently enhances autophagic activity via direct interaction with Beclin-1. This evidence concerns the gene HMGB1 and prostate cancer.